Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

The antibody‐drug conjugate (ADC) tisotumab vedotin (TV) received accelerated approval from the US Food and Drug Administration for treatment of adults with recurrent or metastatic cervical cancer (r/mCC) with disease progression on or after chemotherapy. A population pharmacokinetic (PK) model, dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Passey, Chaitali, Voellinger, Jenna, Gibiansky, Leonid, Gunawan, Rudy, Nicacio, Leonardo, Soumaoro, Ibrahima, Hanley, William D., Winter, Helen, Gupta, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508544/
https://www.ncbi.nlm.nih.gov/pubmed/37496366
http://dx.doi.org/10.1002/psp4.13007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508544/
https://www.ncbi.nlm.nih.gov/pubmed/37496366
http://dx.doi.org/10.1002/psp4.13007

Ejemplares similares